Development and Characterization of Nanoliposomal Hydroxyurea Against BT-474 Breast Cancer Cells

Development and Characterization of Nanoliposomal Hydroxyurea Against BT-474 Breast Cancer Cells

Purpose: Hydroxyurea (HU) is a well-known chemotherapy drug with several side effects which limit its clinical application. This study was conducted to improve its therapeutic efficiency against breast cancer using liposomes as FDA-approved drug carriers. Methods: PEGylated nanoliposomes-containing...

Full description

Bibliographic Details
Main Authors: Azam Akbari, Azim Akbarzadeh, Morteza Rafiee Tehrani, Reza Ahangari Cohan, Mohsen Chiani, Mohammad Reza Mehrabi
Format: Article
Language:English
Published: Tabriz University of Medical Sciences 2020-01-01
Series:Advanced Pharmaceutical Bulletin
Subjects:
breast neoplasms
drug carriers
hydroxyurea
liposomes
Online Access:https://apb.tbzmed.ac.ir/PDF/apb-27500

Internet

https://apb.tbzmed.ac.ir/PDF/apb-27500

Similar Items